Clinical trial · Observational
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy
NCT01884168CI-TRIAL-00073790completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor presenting malignant cavity effusion after DC-CIK immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumor | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dc-CIK immunotherapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- gene expression profile
- description
- T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
- interventionNames
- Biological: Dc-CIK immunotherapy
Primary outcomes (1)
- measure
- Immunotherapy response
- timeFrame
- 1 month
- description
- T-Cell Receptor and B-Cell Receptor gene expression profiling and the change of cytokines, lymphocytes subpopulation before and after DC-CIK infusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed with malignant tumor and malignant cavity effusion. 2. An Eastern Cooperative Oncology Group（ECOG）performance status of 0-2. 3. Normal cardiac, hepatic, renal and bone marrow functions. 4. Life expectancy \>3 months. 5. Not receive other anti-tumor treatment. 6. Not receive chemotherapy in pleural and abdominal cavity. Exclusion Criteria: 1. Previous history of other malignancies. 2. Serious or uncontrolled concurrent medical illness.
References
Publications (0)
Data not yet available
No reference posted for this study.